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Abstract
Recently, fused in sarcoma/translated in liposarcoma (FUS/TLS) gene, located on chromosome 16p11.2, has been identified as a disease
gene in familial amyotrophic lateral sclerosis (FALS). We have analyzed FUS/TLS in a cohort of 52 index cases from seven Italian regions
with non-SOD1 and non-TARDBP FALS. We identified a heterozygous c.G1542C missense mutation in a family of northern Italian origin, and
a heterozygous c.C1574T missense mutation in a family of Sicilian origin. Both variants are located in exon 15 encoding the RNA-recognition
motif, and result in a substitution of an arginine with a serine in position 514 (p.R514S) and substitution of a proline with a leucine at position
525 (p.P525L), respectively. Overall, the two mutations accounted for 3.8% of 52 non-SOD1 and non-TDP43 index cases of FALS. The
clinical phenotype was similar within each of the families, with a predominantly upper limb onset in the family carrying the p.R514S mutation
and bulbar onset, with very young age and a rapid course in the family carrying the p.P525L mutation.
© 2009 Elsevier Inc. All rights reserved.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disorder of cortical, bulbar and spinal motor neurons,
clinically characterized by progressive paralysis and ulti-
mately death due to respiratory failure typically within 3 years
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of symptom onset. Approximately 5% of cases are familial in
nature (FALS), whereas the majority of cases occur sporad-
ically in the community (SALS) (Chiò et al., 2008). Among
FALS, 15–20% are caused by mutations in the superoxide
dismutase (SOD1) gene (Rosen et al., 1993), and a further
5–10% are due to pathogenic mutations in the TAR DNA
binding protein (TARDBP) gene (Sreedharan et al., 2008).
Recently, fused in sarcoma/translated in liposarcoma
(FUS/TLS) gene has been identified as a disease gene in FALS
(Kwiatkowski et al., 2009; Vance et al., 2009). Located on
chromosome 16p11.2, this gene encodes for a 526-amino
0197-4580/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
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acid protein that binds RNA and is known to be involved in
RNA processing. Almost all ALS-linked mutations identified
to date are clustered in the RNA-recognition motif domain
located at the C terminus of the protein.
In this study, we present genetic analysis data on FUS/TLS
in a cohort of 52 index cases from seven Italian regions with
non-SOD1 and non-TARDBP FALS to further define the
spectrum and frequency of FUS/TLS mutations.
2. Methods
2.1. Subjects
DNA sample from 52 index cases with FALS were col-
lected from eight Italian ALS referral centres (Torino, Pavia,
Modena, Bologna, Siena, Roma, Napoli, and Palermo). All
cases were diagnosed as having definite, probable or probable
laboratory-supported ALS according to revised El Esco-
rial criteria (Brooks et al., 2000). Mutations in SOD1 and
TARDBP genes were excluded before the inclusion in the
present study. Control samples were obtained from 280
healthy individuals matched to cases by age, gender, and Ital-
ian region of origin. Written informed consent for genetic
analysis was obtained from each individual.
2.2. Genetic analysis
Genomic DNA was extracted from peripheral blood with
the Biorobot MDX DSP Qiagen. Exons 1–14 of FUS gene
were sequenced as previously described (Vance et al., 2009).
Exon 15 of FUS was PCR amplified with the follow-
ing primers: forward sequence TCGCTGGGTTAGGTAG-
GAGG, reverse sequence TATTCCAGTTCCTGCTGGGC.
PCR products were sequenced using the Big-Dye Termina-
tor v3.1 sequencing kit (Applied Biosystem) and run on an
ABIPrism 3100Avant genetic analyzer. Exon 15 was also
sequenced in 280 control individuals.
3. Results
We performed mutational screening of the FUS gene in
52 index patients from Italian kindreds with familial ALS.
We identified a heterozygous c.G1542C missense mutation
in a family of northern Italian (Piedmont) origin (Family A),
and a heterozygous c.C1574T missense mutation in a sec-
ond family of Sicilian origin (Family B). Both variants are
located in exon 15 encoding the RNA-recognition motif, and
result in a substitution of an arginine with a serine in position
514 (p.R514S) and substitution of a proline with a leucine at
position 525 (p.P525L), respectively. DNA was not available
from other members of either family, so it was not possible to
confirm segregation. However, the mutations were not found
in 280 control samples. Apart from a synonymous mutation
in exon 15 of another FALS index case (c.G1566A), no other
exonic variant was detected.
3.1. Family A (Piedmont, northern Italy)
The index case IV-1 (Fig. 1, Supplementary Table 1) devel-
oped lower limb weakness at 36 years of age. His symptoms
progressed rapidly to involve neck and respiratory muscles
with generalized hyperreflexia. EMG at the time of presen-
tation confirmed acute and chronic alterations in all limbs
and the thoracic muscles. CSF examination and MRI of the
brain and the spinal cord were normal. The patient died of
respiratory failure 22 months after symptom onset.
His father (III-1), an obligate gene carrier, died at 69
years of age from lung cancer without signs of ALS or
Fig. 1. Pedigree of family A with chromatogram of part of exon 15 of FUS showing single base change c.1542G > C in the index patient, substituting arginine
for serine in position 514. Square indicates male; circle, female; slash, deceased; solid symbol, affected; and arrow, index patient.
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Fig. 2. Pedigree of family B. Pedigree of family B with chromatogram of part of exon 15 of FUS showing single base change c.1574C > T in the index patient,
substituting proline for leucine in position 525. Square indicates male; circle, female; slash, deceased; solid symbol, affected; and arrow, index patient.
neuromuscular disorders. Two paternal sisters of the index
case developed hands and shoulder girdle weakness at age 48
(III-5) and 64 (III-6), respectively. Symptoms were rapidly
progressive, were associated with generalized hyperreflexia,
and they died from respiratory failure 25 and 15 months
after onset. The paternal grandfather (II-1) of the index
case developed asymmetrical shoulder girdle weakness at
age 41, and died from respiratory failure 22 months later.
His sister (II-2) developed right hand wasting at 60 years
of age. Her symptoms spread rapidly to involve her bulbar
musculature and she died from respiratory failure 19 months
after symptom onset. The mother of II-1 and II-2 (I-1)
presented with right shoulder atrophy at 52 and died from
respiratory failure 2 years later. Autopsy material was not
available from any of the deceased family members.
3.2. Family B (Sicily, southern Italy)
The index case IV-3 (Fig. 2, Supplementary Table 2)
presented at 21 years of age with a 3-month history of
rapidly progressive bulbar dysfunction. Her symptoms spread
quickly to involve her upper limbs with generalized hyper-
reflexia. EMG at the time of presentation confirmed active
and chronic denervation in upper limbs. CSF examination,
biochemical profile, and MRI brain and spinal cord were nor-
mal. The patient died of respiratory failure less than 1 year
after the onset of ALS.
Both her mother (III-13) and a maternal uncle (III-16)
died at 33 and 17, from aggressive bulbar-onset motor neu-
ron disease leading to respiratory failure in less than 1 year.
Her maternal grandfather (II-7) developed rapidly progres-
sive upper limb atrophy and weakness and respiratory failure
and died less than 2 years later due to respiratory failure.
4. Discussion
In the present paper, we screened a cohort of 52 Italian
patients diagnosed with FALS and identified two multi-
generational families carrying mutations in the FUS gene.
The two mutations accounted for 3.8% of 52 non-SOD1 and
non-TDP43 index cases of FALS, a frequency similar to that
found in series of 197 index cases of British and Australian
FALS kindreds (4.1%) (Vance et al., 2009). Although it was
not possible to confirm segregation of the mutations with
disease within the families, these variants are likely to be
pathogenic, as they were not found in 280 normal Italian con-
trol subjects. Furthermore, although the c.G1542C variant has
not been previously reported, a G to T transversion at the same
base pair leading to the same p.R514S amino acid change
has previously been identified in a FALS case (Kwiatkowski
et al., 2009). Finally, the c.C1574T mutation was also
previously identified in a familial case (Kwiatkowski et al.,
2009).
The clinical phenotype was similar within each of the
families. Family A was characterized by a relatively young
mean age at onset (50 years; SD 11.1), predominantly upper
limb onset, clear UMN involvement, and rapid progression
to respiratory failure and death. Mean disease duration from
onset was 21.2 months (SD 3.7). One obligate carrier (III-1)
deceased at 69 without any sign of ALS, indicating a possible
reduced penetrance.
In contrast to Family A, the clinical phenotype of Family
B is dominated by bulbar dysfunction (presenting symptom
in three out of four cases), a young age at onset (mean,
23.7; SD 7.1) and rapid progression (death in less than
12 months in three out of four of the cases). The clinical
pattern observed in our family is similar to that already
reported for this mutation (mean age of onset = 22 years,
mean disease duration = 6 months) (Kwiatkowski et al.,
2009) confirming that this particular FUS mutation results
in a highly aggressive form of ALS.
In summary, the identification of two Italian kindreds of
different origin with FALS due to FUS/TLS missense muta-
tions indicates the widespread diffusion of this mutation.
Together with the figures reported in other studies (Vance et
al., 2009), it seems that the occurrence of FUS/TLS mutations
is about 4% of non-SOD1 and non-TDP43 FALS.
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